Scalper1 News
Credit Suisse raised its price target on Kite Pharma (KITE), a day after the cancer treatment developer announced a significant deal with Amgen. Jason Kantor maintained an outperform rating on Kite and raised his price target to 79 from 71. Kite stock was up 3.5%, near 72, in afternoon trading on the stock market today. Kite stock touched a new high for the third straight trading day. On Tuesday, Kite announced the European Commission “has Scalper1 News
Scalper1 News